Royalty Report: Drugs, Disease, HIV / AIDs – Collection: 203504

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Disease
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203504

License Grant
Licensor grants an exclusive (even as to  Licensor), license under the Patent Assets and Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, market and sell and otherwise dispose of Compound and Product, including any Improvements thereto, in the Territory.
License Property
The Licensed products contain the compound.  The Compound shall mean a condensation polymer of an aromatic sulfonic acid and an aldehyde or a pharmaceutically acceptable salt or prodrug thereof or a derivative, homolog, or analog thereof.
Field of Use
The Compound is for a candidate topical microbicide used to prevent infection by the human immunodeficiency virus (HIV) and other sexually transmitted pathogens.

IPSCIO Record ID: 279299

License Grant
This agreement is to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.

For the License of proprietary rights,  Licensor grants a co-exclusive, with Licensor, worldwide right and license, without the right to sublicense, within the Territory, to use the Licensor Intellectual Property and Licensor Patent Rights and the Program Intellectual Property owned by Licensor, in each case with application to the Field to the extent necessary or useful to research, develop, have developed, make, have made, use, distribute, promote, market, offer for sale, sell, have sold, import and export Designated Shared Compounds, Derivative Compounds thereof, Shared Products and, to the extent permitted Independent Compounds, Derivative Compounds thereof and Independent Products.

The research license portion is non-exclusive.

License Property
ALIS means the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

Licensor will screen at least five million (5,000,000) compounds contained in the Licensor NeoMorph Screening Library against each Shared Target.

Licensee will provide at least two hundred fifty (250) nmol. of each of the purified functionally-active Shared Target proteins.

Derivative Compounds means any analogs, homologs or isomers of a Designated Shared Compound and/or an Independent Compound, as applicable.

Field of Use
Field means all preventative, therapeutic and diagnostic uses of Shared Products or Independent Products with respect to human immunodeficiency virus (HIV) in humans.

Licensee is interested in identifying potential pharmaceutical products for the treatment of human immunodeficiency virus (HIV) and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.

IPSCIO Record ID: 281539

License Grant
This agreement is to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.

Licensor grants a co-exclusive with Licensor, worldwide right and license, without the right to sublicense, within the Territory, to use the Licensor Intellectual Property and Licensor Patent Rights and the Program Intellectual Property owned by Licensor, in each case with application to the Field to the extent necessary or useful to research, develop, have developed, make, have made, use, distribute, promote, market, offer for sale, sell, have sold, import and export Designated Shared Compounds, Derivative Compounds thereof and Shared Products and, to the extent permitted Independent Compounds, Derivative Compounds thereof and Independent Products.

The research license portion is non-exclusive.

License Property
ALIS means the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to Licensee that is used to identify multiple classes of chemical ligands against a target protein.

Licensee will screen at least five million (5,000,000) compounds contained in the Licensee NeoMorph Screening Library against each Shared Target.

Licensor will provide Licensee with at least two hundred fifty (250) nmol. of each of the purified functionally-active Shared Target proteins.

Derivative Compounds means any analogs, homologs or isomers of a Designated Shared Compound and/or an Independent Compound, as applicable.

Field of Use
Field means all preventative, therapeutic and diagnostic uses of Shared Products or Independent Products with respect to human immunodeficiency virus (HIV) in humans.

IPSCIO Record ID: 289184

License Grant
Foundation grants to Licensee the exclusive right and license to make, have made, use, import, offer for sale, and sell in the Territory, Licensed Products during the term of this Agreement including Licensee’s right to grant sublicenses.

The license granted is subject to a reserved, non-exclusive license of Foundation, transferable to University and its not-for-profit academic collaborators, to practice the Licensed Patents in the Field, only for the purpose of non-commercial scientific inquiry, academic research, and education.

License Property
Licensed Product means any compound, product, service, or process in the Field, the manufacture, use, or sale of which, but for the license granted herein, would infringe at least one Valid Claim.

Licensed Patents means (i) the patent applications listed, (ii) the United States patents that may issue from the patent applications listed and from divisionals and continuations and continuations-in-part of such United States patents and patent applications, (iii) all foreign counterparts of such patent applications, and all patents that issue thereon anywhere in the world, including reexamined and reissued patents. Licensed Patents shall also mean any patent application having claims in the Field directed to an invention made in the laboratory of Dr. Vasu Nair six months or less prior to the Effective date, and (iv) with respect to the matters described in clauses (i), (ii) and (iii) above, all provisionals, renewals, re-examinations, patents of addition, supplementary protection certificates, extensions, restorations of patent terms, letters of patent, registration or confirmation patents and reissues of such patents or patent applications.
7,250,421 – Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase

Indication shall mean the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with a specific virus in the Field. For example HIV Indication means the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with Human Immunodeficiency Virus (HIV) and HCV Indication means prevention, treatment or diagnosis of a condition, infection or a disease caused by or associated with Hepatitis C Virus (HCV).

Field of Use
Field means any and all anti-viral uses, including but not limited to prophylaxis, diagnosis or treatment of a condition, infection or disease associated with a virus, except the Field specifically excludes any anti-viral use associated with (a) the following DNA virus families:  poxviridae, polyomaviridae, papillomaviridae, adenoviridae, and parvoviridae; and (b) all RNA viruses except for the following RNA virus families, which are specifically included in the Field:  retroviridiae (for example HIV as defined below), flaviviridae (for example HCV as defined below), orthomyxoviridae, paramyxoviridae, and coronaviridae. In the event that Licensee terminates the Sponsored Research Agreement (“SRA”), a copy of which is attached as Appendix J, pursuant to paragraph 16(d) of the SRA, the Field of this License Agreement shall automatically be amended to exclude HCV.

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.